Product vision |
- Uncomplicated malaria treatment and resistance management
|
MoA |
- Novel mechanism - inhibition of acetylCoA synthetase
|
Key features |
|
Challenges |
- Synthetic route optimization
- Low melting point compound with poor yield from final recrystallisation step
|
Status |
- Nonclinical development – Good Laboratory Practice (GLP) general toxicology complete
|
Next milestone |
- Complete GLP safety pharmacology package
- Good Manufacturing Practice (GMP) drug substance synthesis
|
Previously |
- Discovery collaboration with TropIQ
|
MMV Project Director |
|